Clinical use of sildenafil in pulmonary artery hypertension

Expert Review of Respiratory Medicine

Volumn 4, Issue 1, 2010, Pages 13-19

  Singh, T P ^a  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

Author keywords

Nitric oxide; Phosphodiesterase inhibitors; Pulmonary artery hypertension; Pulmonary vasodilators; Sildenafil

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; DIURETIC AGENT; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VASODILATOR AGENT; VERDANAFIL;

ABDOMINAL DISCOMFORT; BLOOD PRESSURE; BLURRED VISION; CARDIOVASCULAR DISEASE; CHILL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPISTAXIS; ERECTILE DYSFUNCTION; FACE EDEMA; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HOT FLUSH; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; MALAISE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORTALITY; NAUSEA; NOSE CONGESTION; OPTIMAL DRUG DOSE; OXYGEN THERAPY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PRIAPISM; PULMONARY HYPERTENSION; RETINOPATHY; REVIEW; SIDE EFFECT; STROKE; SURVIVAL TIME; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; VISUAL DISORDER;

EID: 77951627369     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.71     Document Type: Review

References (42)

1. D'Alonzo GE, Barst RJ, Ayees SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. 115, 343-349 (1991).
2. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 107, 216-223 (1987). (Pubitemid 17137857)
3. Hatano S, Strasser T. Primary Pulmonary Hypertension: report on a WHO meeting. Geneva, 15-17 October 1973. WHO, Geneva, Switzerland (1975).
4. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42, 1163-1184 (1970).
5. Fishman A P. Clinical classifcation of pulmonary hypertension. Clin. Chest Med. 22, 385-391 (2001).
6. Simonneau G, Galie N, Rubin LJ et al. Clinical classifcation of pulmonary hypertension. J. Am. Coll. Cardiol. 43, S5-S12 (2004).
7. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classifcation of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54 (2009).
8. Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Med. J. Aust. 178, 564-567 (2003).
9. Jackson G, Gillies H, Osterlo I. Past present and future: a 7 year update of Viagra (sildenafl citrate). Int. J. Clin. Pract. 59, 680-691 (2005).
10. Corbin JD. Mechanism of action of PDE-5 inhibition in erectile dysfunction. Int. J. Impot. Res. 16(Suppl. 1), S4-S7 (2004).
11. Rashid A. The effcacy and safety of PDE-5 inhibitors. Clin. Cornerstone 7, 47-56 (2005).
12. Karatza AA, Bush A, Magee AG. Safety and effcacy of sildenafl therapy in children with pulmonary hypertension. Int. J. Cardiol. 100(2), 267-273 (2005).
13. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafl, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 125(2), 580-586 (2004).
14. Wilkins MR, Wharton J. Progress in and future prospects for the treatment of primary pulmonary hypertension. Heart 86, 603-604 (2001).
15. Cohen AH, Hanson K, Morris K et al. Inhibition of cyclic 3́-5́ guanosine monophosphate-specifc phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97, 172-179 (1996).
16. Mehta S. Sildenafl for pulmonary arterial hypertension: exciting, but protection required. Chest 123(4), 989-992 (2003).
17. Kothari SS, Duggal B. Chronic oral sildenafl therapy in severe pulmonary artery hypertension. Indian Heart J. 54, 404-409 (2002).
18. Sastry BK, Narasmhan C, Reddy NK et al. Clinical effcacy of sildenafl in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 43(7), 1149-1153 (2004).
19. Kataoka M, Satoh T, Manabe T et al. Oral sildenafl improves primary pulmonary hypertension refractory to poprostenol. Circ. J. 69(4), 461-465 (2005).
20. Lee AJ, Chiao TB, Tsang MP. Sildenafl for pulmonary hypertension. Ann. Pharmacother. 39(5), 869-884 (2005).
21. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A metaana lysis of randomized controlled trials in pulmonary artery hypertension. Eur. Heart J. 30, 394-403 (2009).
22. Ng J, Finney SJ, Shulman R, Bellingan GJ, Singer M, Glynne PA. Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafl? Br. J. Anaesth. 94(6), 774-777 (2005).
23. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the effcacy of oral sildenafl therapy in severe pulmonary artery hypertension. Am. Heart J. 151(4), 851.e1-851.e5 (2006).
24. Galiè N, Ghofrani HA, Torbicki A et al. Sildenafl citrate therapy for pulmonary arterial hypertension. SUPER (Sildenafl Use in Pulmonary Arterial Hypertension) Study Group. N. Engl. J. Med. 353(20), 2148-2157 (2005).
25. Robyn J, Barst J, Gibbs SR et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S78-S84 (2009).
26. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafl is an effective and specifc pulmonary vasodilator in patients with pulmonary artery hypertension: comparison with nitric oxide. Circulation 105, 2398-2403 (2002).
27. Leproe JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM. Effect of sildenafl on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am. J. Cardiol. 90, 677-680 (2002).
28. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B. Effect of inhaled iloprost plus oral sildenafl in patients with primary pulmonary hypertension. Circulation 104, 1218-1222 (2001).
29. Ghofrani HA, Wiedmann R, Rose F, Olschewski H, Schermuly RT, Weissmann N. Combination therapy with oral sildenafl and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136, 515-522 (2002).
30. Ghofrani HA, Wiedmann R, Rose F, Olschewski H, Schermuly RT, Weissmann N. Sildenafl for treatment of lung fbrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360, 895-900 (2002).
31. Wilkins MR, Paul GA, Strange JW et al. Sildenafl versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 171(11), 1292-1297 (2005).
32. Ghofrani HA, Voswinckel R, Reighenberger F et al. Difference in hemodynamic and oxygenation response to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension-randomized prospective study J. Am. Coll. Cardiol. 44, 1488-1496 (2004).
33. Ghofrani HA, Rose F, Schermuly RT et al. Oral sidlenafl as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42, 158-164 (2003).
34. Bhatia S, Frantz F, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafl in patients with pulmonary arterial hypertension receiving vasodilators therapy. Mayo Clin. Proc. 78, 1207-1213 (2003).
35. Simmoneau G, Burgess G, Collings L et al. Safety and effcacy of combination therapy with sildenafl and epoprostenol in patients with PAH. Am. J. Respir. Crit. Care Med. 173, A58 (2006).
36. Simmoneau G, Rubin LJ, Galie N et al. (PACES study group). Addition of sildenafl to long term intravenous epoprostenol therapy in patients with pulmonary artery hypertension. Ann. Intern. Med. 149, 521-530 (2008).
37. Simmoneau G, Rubin LJ, Galie N et al. Safety and effcacy of sildenafl-epoprostenol combination in patients with PAH. Am. J. Respir. Crit. Care Med. 175, A300 (2007).
38. Mathai SC, Girgis RE, Fisher MR et al. Addition of sildenafl to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J. 29, 469-475 (2007).
39. Viagra (sildenafl)™, package insert. Pfzer Labs, New York, NY, USA.
40. Mikhail GW, Prasad SK, Li W et al. Clinical and hemodynamic effects of sildenafl in pulmonary hypertension: acute and mid-term effects. Eur. Heart J. 25, 431-436 (2004).
41. Laties AM, Zrenner E. Viagra (sildenafl citrate) and ophthalmology Prog. Retin. Eye Res. 21, 485-506 (2002).
42. Rubin LJ, Badesch D, Fleming T et al. Long term treatment with sildenafl citrate in pulmonary arterial hypertension. Chest 134(4), S40003 (2008).